[{"id":"0e951a08-185b-43b0-abfd-bacd8cecb2d9","acronym":"PINNACLE","url":"https://clinicaltrials.gov/study/NCT05378763","created_at":"2022-05-18T13:00:48.132Z","updated_at":"2024-07-02T16:35:19.182Z","phase":"Phase 3","brief_title":"A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations","source_id_and_acronym":"NCT05378763 - PINNACLE","lead_sponsor":"Spectrum Pharmaceuticals, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Pozenveo (poziotinib)"],"overall_status":"Suspended","enrollment":" Enrollment 268","initiation":"Initiation: 05/12/2022","start_date":" 05/12/2022","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2024-02-15"},{"id":"e4d27370-be7e-4e92-8c11-59cc09f2312e","acronym":"R2D2","url":"https://clinicaltrials.gov/study/NCT03845270","created_at":"2021-01-18T18:59:02.788Z","updated_at":"2024-07-02T16:35:25.781Z","phase":"Phase 2","brief_title":"Her2-positive Lung Cancer Treated With Dedicated Drug","source_id_and_acronym":"NCT03845270 - R2D2","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 insertion • HER-2 L755S • HER-2 exon 20 mutation • HER-2 YVMA • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 insertion • HER-2 L755S • HER-2 exon 20 mutation • HER-2 YVMA • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 05/17/2019","start_date":" 05/17/2019","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 12/18/2023","study_completion_date":" 12/18/2023","last_update_posted":"2023-12-19"},{"id":"db94dab1-91ab-404b-ac8a-f0cbedaa2ba2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04311034","created_at":"2021-01-18T20:54:00.404Z","updated_at":"2024-07-02T16:35:25.956Z","phase":"Phase 1/2","brief_title":"A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04311034","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2 • MET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation","tags":["HER-2 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/26/2018","start_date":" 09/26/2018","primary_txt":" Primary completion: 12/21/2021","primary_completion_date":" 12/21/2021","study_txt":" Completion: 05/30/2022","study_completion_date":" 05/30/2022","last_update_posted":"2023-12-18"},{"id":"5099b846-9a06-490a-87e5-9edae2154cd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05745740","created_at":"2023-02-27T15:01:09.062Z","updated_at":"2024-07-02T16:35:28.037Z","phase":"Phase 1/2","brief_title":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","source_id_and_acronym":"NCT05745740","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-27"},{"id":"ea7b0831-aa27-4710-8ad0-16bc4a75633a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06067776","created_at":"2023-10-05T16:11:05.700Z","updated_at":"2024-07-02T16:35:34.583Z","phase":"Phase 1","brief_title":"Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer","source_id_and_acronym":"NCT06067776","lead_sponsor":"Jonathan Riess","biomarkers":" HER-2 • BRAF • ALK • MET • RET","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation","tags":["HER-2 • BRAF • ALK • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-10-05"},{"id":"3163b35c-7b87-40b8-a46f-d3b003617156","acronym":"COGNITION-GUIDE","url":"https://clinicaltrials.gov/study/NCT05332561","created_at":"2022-04-18T15:52:52.238Z","updated_at":"2024-07-02T16:35:43.885Z","phase":"Phase 2","brief_title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","source_id_and_acronym":"NCT05332561 - COGNITION-GUIDE","lead_sponsor":"German Cancer Research Center","biomarkers":" HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • PD-L1 amplification • HR positive + HER-2 negative • HER-2 exon 20 mutation • UGT1A1*28 • UGT1A1*1*1 • HER-2 exon 23 mutation","tags":["HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • PD-L1 amplification • HR positive + HER-2 negative • HER-2 exon 20 mutation • UGT1A1*28 • UGT1A1*1*1 • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2023-07-06"},{"id":"1978da50-39bd-4ed1-bae5-634d56f98b7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800340","created_at":"2023-04-05T14:03:39.507Z","updated_at":"2024-07-02T16:35:51.386Z","phase":"Phase 2","brief_title":"Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC","source_id_and_acronym":"NCT05800340","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • PD-L1 • BRAF • MET • RET","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2 • PD-L1 • BRAF • MET • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/04/2023","start_date":" 04/04/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-04-05"},{"id":"c52db608-0147-4e7b-a4a9-1aa8cea334b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04382300","created_at":"2021-01-18T21:09:42.983Z","updated_at":"2024-07-02T16:36:35.432Z","phase":"Phase 2","brief_title":"Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions","source_id_and_acronym":"NCT04382300","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • thalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2021-01-28"},{"id":"c9f77032-3d78-42e6-a36e-d332ab921330","acronym":"","url":"https://clinicaltrials.gov/study/NCT02827357","created_at":"2021-01-18T13:51:45.339Z","updated_at":"2024-07-02T16:37:30.750Z","phase":"","brief_title":"Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation","source_id_and_acronym":"NCT02827357","lead_sponsor":"University Hospital, Toulouse","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2016-07-11"}]